Pegvisomant dosage in published studies and labels

These are the doses used for Pegvisomant in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Pegvisomant has an FDA-approved human dosage as Somavert, for acromegaly when surgery or radiation have not worked well enough or are not appropriate. The label gives a 40 mg subcutaneous loading dose under supervision, then 10 mg once daily from the next day, adjusted in 5 mg steps every 4–6 weeks to keep serum IGF-1 in the normal range, within 10–30 mg once daily.

FDA Approved

Dosage evidence summary for Pegvisomant
Human dosing established	Yes
Studied dose range	10–30 mg once daily after a 40 mg loading dose
Route	Subcutaneous
Frequency	Once daily, after a single loading dose
Duration studied	Continuous
Titration	Measure serum IGF-1 every 4–6 weeks; raise the dose by 5 mg if IGF-1 is high and lower it by 5 mg if IGF-1 is below normal, within 10–30 mg once daily. The label says not to adjust the dose by growth hormone levels or symptoms.
Half-life	Mean half-life estimates of 60 to 138 hours after single or multiple doses (Somavert label)
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Pegvisomant, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Somavert, acromegalyFDA-approved label · FDA prescribing information	Adults with acromegaly who had an inadequate response to surgery or radiation, or for whom these are not appropriate	40 mg loading dose, then 10 mg daily; range 10–30 mg, maximum 30 mg daily	Subcutaneous, upper arm, upper thigh, abdomen or buttocks	Once daily	Continuous; titrated against serum IGF-1	In the label's 12-week placebo-controlled study (112 patients), mean IGF-1 fell by 27%, 48% and 63% with 10, 15 and 20 mg/day, against 4% with placebo	SOMAVERT (pegvisomant) for injection — FDA prescribing information, DailyMed

Where sources disagree

Pegvisomant blocks the growth hormone receptor. It lowers IGF-1 rather than raising it, so it works in the opposite direction to growth hormone products.
The label asks for liver tests before starting and lists liver toxicity as a warning. It also warns that glucose tolerance may improve, so people with diabetes may need lower doses of their diabetes medicines to avoid hypoglycaemia.
Somavert comes as single-dose vials of powder (10, 15, 20, 25 or 30 mg) packed with a prefilled syringe of 1 mL sterile water; each vial is reconstituted with that syringe and used immediately. The label says not to shake the vial.